Skip to main content
Figure 6 | Molecular Pain

Figure 6

From: ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response

Figure 6

Effect of ARA 290 on GFAP immunoreactivity on L1-L6 spinal cord segments of animals 2 and 20 weeks after spared nerve injury. A. Representative photomicrographs of GFAP immunoreactivity (green) in the lumbar dorsal horns of animals 2 weeks after spared nerve injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290 (second row) or 30 μg/kg ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In each column, the GFAP immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show higher magnifications of the photomicrographs. B. Representative photomicrographs of GFAP immunoreactivity (green) in the lumbar dorsal horns of animals 20 weeks after spared nerve injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290 (second row) or 30 μg/kg ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In each column, the GFAP immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show higher magnifications of the photomicrographs.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us